Meridia sibutramine regulatory update

EMEA's CHMP recommended the suspension of marketing for anti-obesity sibutramine from Abbott after a safety review indicated an increased risk of cardiovascular events. CHMP said physicians in Europe should not issue any new prescriptions for sibutramine, which is marketed in Europe as Reductil, Reduxade and Zelium. ...